Imugene (ASX:IMU) Preferred Dividends : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Imugene Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Imugene's preferred dividends for the six months ended in Dec. 2023 was A$0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Imugene Preferred Dividends Historical Data

The historical data trend for Imugene's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene Preferred Dividends Chart

Imugene Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Preferred Dividends

Get a 7-Day Free Trial

Imugene Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Imugene Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Imugene (ASX:IMU) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Imugene (ASX:IMU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

IUGNF:USA

Address

4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000

Website

https://www.imugene.com

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.

Imugene (ASX:IMU) Headlines

No Headlines